Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
65.40    1.40 (2.19%)
Bid:
65.10
Ask:
65.90
Spread: 0.80 (1.229%)
Market Cap: £577.76m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Completion of share buyback programme

20 Nov 2025 07:00

RNS Number : 2623I
IP Group PLC
20 November 2025
 

20 November 2025

 

IP Group plc

 

Completion of Share Buyback Programme

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), announces that on 18 November 2025 it successfully completed the £20m extension to its share buyback programme that was originally announced on 26 June 2025. 

 

Since commencing its buyback programme, the Group has purchased 157,968,634 shares at an average price of 47.5 pence per share for an aggregate consideration of £75m ("the Buyback Programme"). All shares acquired under the Buyback Programme have been, or will shortly be, cancelled.

 

Following such cancellation, the Company's issued share capital consists of 883,427,642 Ordinary Shares with voting rights and there are no Ordinary Shares held in treasury. This figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Share buybacks will remain an important part of IP Group's Capital Allocation Policy. The Group will keep further buybacks under review, subject to the achievement of additional realisations within the portfolio.

 

For more information, please contact:

 

IP Group plc

 

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

 

Portland

Alex Donaldson

+44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science investor, we develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech. Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, Featurespace, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London

 

ENDS

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAEFNFELSFAA
Date   Source Headline
6th Jul 20187:00 amRNSNotification of Major Interest in Shares
4th Jul 20182:40 pmRNSCeres Power announces £20m fundraising
2nd Jul 20187:00 amRNSHolding(s) in Company
27th Jun 20187:30 amRNSCarisma announces $53m Series A funding round
27th Jun 20187:00 amRNSNotification of Major Interest in Shares
22nd Jun 201810:00 amRNSAppointment of Joint Broker
18th Jun 20181:37 pmRNSResult of AGM
7th Jun 20186:00 pmRNSHolding(s) in Company
6th Jun 20189:26 amRNSMicrobiotica signs collaboration worth up to $534m
16th May 201810:49 amRNSPortfolio co Ceres partners with Weichai Power
16th May 20187:00 amRNSNotice of AGM; Annual Report
11th May 20187:00 amRNSDirector/PDMR Shareholding
10th May 20186:18 pmRNSDirector/PDMR Shareholding
9th May 20185:31 pmRNSDirector share purchase
4th May 20187:00 amRNSBoard changes
30th Apr 20187:00 amRNSTotal Voting Rights
16th Apr 20185:45 pmRNSDirector/PDMR Shareholding
12th Apr 20189:19 amRNSEnterprise Therapeutics raises £29m
5th Apr 20181:12 pmRNSIP Group plc - Issue of Equity
4th Apr 201811:46 amRNSIP Group plc - Director/PDMR share purchase
29th Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSOxford Nanopore announces £100m fundraising
17th Jan 201811:53 amRNSHolding(s) in Company
10th Jan 20189:12 amRNSHolding(s) in Company
2nd Jan 20187:00 amRNSTotal Voting Rights
18th Dec 201710:15 amRNSAutifony signs Eur627.5m agreement with BI
15th Dec 201712:50 pmRNSDiurnal receives positive CHMP opinion for Alkindi
14th Dec 20174:48 pmRNSDirectorate Change
13th Dec 20172:27 pmRNSIssue of Equity
8th Dec 20177:05 amRNSMirriad raises £26.2m; proposed admission to AIM
6th Dec 20172:32 pmRNSIssue of Equity
30th Nov 201712:40 pmRNSTotal Voting Rights
27th Nov 20176:27 pmRNSIssue of Equity
22nd Nov 20175:50 pmRNSHolding(s) in Company
22nd Nov 20173:23 pmRNSIssue of Equity
15th Nov 201712:47 pmRNSIssue of Equity
14th Nov 201712:29 pmRNSHolding(s) in Company
13th Nov 20177:00 amRNSNotice of cancellation of admission to AIM
9th Nov 201711:11 amRNSIssue of Equity
8th Nov 20175:11 pmRNSHolding(s) in Company
6th Nov 20173:50 pmRNSIssue of Equity
6th Nov 20177:00 amRNSHolding(s) in Company
2nd Nov 20177:00 amRNSHolding(s) in Company
31st Oct 20175:35 pmRNSHolding(s) in Company
31st Oct 20175:20 pmRNSTotal Voting Rights
26th Oct 20173:50 pmRNSIssue of Equity
19th Oct 20173:20 pmRNSForm 8.3 - IP Group PLC
19th Oct 201710:38 amRNSForm 8.5 (EPT/RI) - IP Group Plc
18th Oct 20175:02 pmRNSForm 8.5 (EPT/RI) - IP Group Plc Amendment
18th Oct 20173:20 pmRNSForm 8.3 - IP Group PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.